| Single‐and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults JC Nussbaum, A Hussain, P Butera, AP Ford, MM Kitt, EA O'Neill, S Smith, ... The Journal of Clinical Pharmacology, 2024 | | 2024 |
| Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) AP Ford US Patent App. 18/198,191, 2023 | | 2023 |
| Alpha1a-adrenergic receptor agonists and methods of use DS Carter, C O'yang, AP Ford, W Chen US Patent App. 18/022,949, 2023 | | 2023 |
| Compositions and methods for improving neurological diseases and disorders AP Ford, G Vargas, W Chen, RS Martin US Patent App. 18/023,693, 2023 | | 2023 |
| Fingerprinting heterocellular β-adrenoceptor functional expression in the brain using agonist activity profiles RA Matt, FG Westhorpe, RF Romuar, P Rana, JR Gever, AP Ford Frontiers in Molecular Biosciences 10, 1214102, 2023 | 1 | 2023 |
| Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease RA Matt, RS Martin, AK Evans, JR Gever, GA Vargas, M Shamloo, ... | 2 | 2023 |
| Methods for improving neurological diseases and disorders AP Ford, G Vargas US Patent App. 18/107,886, 2023 | | 2023 |
| Compositions and methods for improving neurological diseases and disorders AP Ford, G Vargas, W Chen, RS Martin US Patent App. 17/986,797, 2023 | | 2023 |
| P2X3 receptor antagonism attenuates the progression of heart failure RM Lataro, DJA Moraes, FN Gava, ACM Omoto, CAA Silva, F Brognara, ... Nature Communications 14 (1), 1725, 2023 | 12 | 2023 |
| Methods for improving neurological diseases and disorders AP Ford, G Vargas US Patent 11,607,395, 2023 | | 2023 |
| Substituted pyrazole-pyrimidines, variants thereof, and uses therefore RC Hawley, P Ibrahim, AP Ford, JR Gever US Patent 11,591,315, 2023 | | 2023 |
| Methods for treating neurological disorders with α1A-AR partial agonists AP Ford US Patent 11,590,107, 2023 | | 2023 |
| Effects of clenbuterol, an oral, CNS–penetrant β2 adrenoceptor agonist, on cognition and emotional processing in patients with parkinson’s disease G Vargas, RS Martin, K Hirshhorn, W Riedel, A Malik, SN Millard, ... Neuroscience Applied 2, 102983, 2023 | | 2023 |
| Methods for treating neurological disorders with alpha1a-ar partial agonists AP Ford US Patent App. 17/770,276, 2022 | | 2022 |
| Beta adrenergic agonist and methods of using the same AP Ford, J Yu, DS Carter, W Chen US Patent App. 17/620,065, 2022 | | 2022 |
| Clinical formulation bridging of gefapixant, a P2X3‐receptor antagonist, for the treatment of chronic cough P Gupta, A Hussain, AP Ford, S Smith, JC Nussbaum, A Stoch, M Iwamoto Clinical Pharmacology in Drug Development 11 (9), 1054-1067, 2022 | 6 | 2022 |
| Beta adrenergic agonist and methods of using the same AP Ford, W Chen, DS Carter, J Yu US Patent App. 17/440,705, 2022 | | 2022 |
| A randomized, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of 3 weeks of orally administered gefapixant in healthy younger and older … J Nussbaum, A Hussain, A Ford, P Butera, M Kitt, S Smith, A Stoch, ... Lung 200 (3), 315-323, 2022 | 2 | 2022 |
| Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough AP Ford, KS Glaub, S Smith US Patent App. 17/582,485, 2022 | | 2022 |
| Dose-dependent response of cerebral blood flow in healthy volunteers following administration of β2-adrenergic receptor agonist clenbuterol C Bishop, T Lodeweyckx, JD Hoon, KV Laere, M Koole, W Vandenberghe Conference reports: international society for magnetic imaging in medicine, 2022 | 2 | 2022 |
